Numinus Wellness Inc. announce that its research site, Cedar Clinical Research (CCR), has been chosen as one of multiple sites for Beckley Psytech's cutting-edge Phase 2b clinical trial for Treatment Resistant Depression (TRD). The study aims to evaluate the efficacy and safety of different doses of Beckley Psytech's proprietary intranasal formulation of synthetic 5-Methoxy-N, N- Dimethyltryptamine (5-MeO-DMT) ­ known as BPL-003 ­ as a potential therapy for TRD. It follows Beckley Psytech's receipt of the U.S. Food and Drug Administration's (FDA) first-ever Investigational New Drug (IND) approval for a Phase 2b study of a short-acting psychedelic compound in February this year.

CCR's selection as a clinical research site for this trial further establishes it as a leader in psychedelic clinical research and builds upon its commitment to forging collaborations that explore new mental health solutions. Numinus and CCR's collaboration with Beckley Psytech reflects a unified drive for innovation in psychedelic-assisted therapies. As leaders in mental health solutions, they eagerly anticipate the transformative insights this Phase 2b trial will offer to the broader medical community.